ArticleBMC women's health2025
Application of high intensity focused ultrasound in the treatment of uterine fibroids in overweight/obese women.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Contemporary Management of Uterine Fibroids.Journal of clinical medicine · 2026Review
- Comparison of the perioperative complications of high intensity focused ultrasound vs. laparoscopic surgery for uterine fibroids: a retrospective study.Frontiers in surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo investigate the clinical efficacy and safety of High-Intensity Focused Ultrasound (HIFU) in the treatment of uterine fibroids in overweight/obese women.
methodsA retrospective analysis was conducted on the clinical data of 155 overweight/obese women with uterine fibroids treated at our hospital between January 2022 and January 2024. Among them, 75 patients underwent HIFU treatment (observation group), while 80 patients received conventional laparoscopic myomectomy (control group). Perioperative indicators, symptom improvement (assessed by the Symptom Severity Score, SSS), health-related quality of life (HRQL score), complications, and recurrence rates at 1-year post-treatment were compared between the two groups.
resultsAll procedures were successfully completed in both groups. No significant differences were observed in baseline characteristics such as age, BMI, number of fibroids, maximum fibroid diameter, and hemoglobin levels between the two groups (P > 0.05). At 6 months and 1 year post-treatment, the observation group showed significantly better SSS scores (12.61 ± 1.22 vs. 15.89 ± 1.21; 10.40 ± 1.27 vs. 12.03 ± 1.33) and HRQL scores (89.35 ± 1.90 vs. 84.69 ± 1.24; 94.19 ± 1.16 vs. 91.69 ± 1.32) compared to the control group (P < 0.05). The total complication rate in the observation group was significantly lower than that in the control group (9.33% vs. 21.3%, χ² = 4.34, P = 0.04). No recurrence or fibroid enlargement was observed in the observation group at 1-year follow-up.
conclusionHIFU is an effective and safe treatment for uterine fibroids in overweight/obese women, offering advantages such as minimal invasiveness, fewer complications, and faster recovery. It represents a superior minimally invasive option for this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.